The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Melissa Mitri, Registered Dietitian and weight loss expert at Melissa Mitri Nutrition, about real-world nutrition strategies for patients using GLP-1 therapies. She focuses on nutrient density, meal structure, side effect management, muscle preservation, and long-term habit building. Melissa shares clinical insights from nearly two decades of practice working directly with patients. Melissa highlights how nutrition and lifestyle optimize outcomes alongside GLP-1 medications. Listen now on all major platforms!

“GLP-1 therapies shift nutrition counseling away from calorie obsession toward nutrient density, because patients eat smaller portions and every bite must support metabolic health.”

Meet the guest: Melissa Mitri, MS, RD, is a Registered Dietitian, weight loss expert, and founder of Melissa Mitri Nutrition. She specializes in sustainable weight management, including nutrition support for patients using GLP-1 therapies. With nearly 20 years of clinical experience, her work focuses on nutrient density, habit formation, and evidence based care. 

Connect with our guest on Social Media:
LinkedIn
Instagram
GLP-1 Cheat Sheet for Clinicians

What you will learn:
(00:00) Highlight
(00:45) Introduction
(02:27) Nutrition approach
(04:59) Meal timing
(07:23) Side effects
(12:14) Muscle preservation
(17:35) Long-term habits
(29:49) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.
Website: The GLP-1 Podcast Show
Instagram: The GLP-1 Podcast Show
LinkedIn: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Ken Fujioka, Clinical Professor of Medicine and Director of the Nutrition and Metabolic Research Center at Scripps Clinic, about the clinical evolution of GLP-1-based therapies. He covers next-generation dual and triple agonists, dose titration, nausea management, and long-term weight maintenance. Dr. Fujioka also examines oral alternatives, safety concerns, and real-world prescribing considerations. Listen now on all major podcast platforms!

"Combining multiple satiety hormones allows greater weight reduction by targeting complementary brain and gastrointestinal pathways involved in appetite regulation."

Meet the guest: Dr. Ken Fujioka is a Clinical Professor of Medicine and Director of the Nutrition and Metabolic Research Center at Scripps Clinic, specializing in obesity, diabetes, and metabolic disease management. His work focuses on clinical trials, patient-centered weight treatment, and GLP-1-based therapies.

What you will learn:
(00:00) Highlight
(00:57) Introduction
(02:59) New GLP-1 agents
(05:12) Dose titration
(08:14) Glucagon role
(10:29) Clinical precautions
(12:53) Oral alternatives
(22:42) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.
Website: The GLP-1 Podcast Show
Instagram: The GLP-1 Podcast Show
LinkedIn: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Jens Juul Holst, Professor of Medical Physiology at the University of Copenhagen and Senior Group Leader at the Novo Nordisk Foundation Center for Basic Metabolic Research. We explore the discovery of GLP-1, its evolution into today’s leading therapies for diabetes and obesity, and the molecular and clinical mechanisms that drive their success. Listen now on all major platforms.

“The incretin hormones GLP-1 and GIP amplify insulin secretion after meals, ensuring glucose tolerance and maintaining energy balance across multiple tissues.”

Meet the guest: Dr. Jens Juul Holst is Professor of Medical Physiology at the University of Copenhagen and Senior Group Leader at the Novo Nordisk Foundation Center for Basic Metabolic Research. His research focuses on metabolic hormones, appetite regulation, and the pathophysiology of obesity and type 2 diabetes. Known for co-discovering GLP-1, his work has shaped modern metabolic therapy. 

What you will learn:
(00:00) Highlight
(00:58) Introduction
(02:07) GLP-1 mechanism
(05:00) Discovery process
(07:35) Therapeutic development
(11:19) Cardiovascular effects
(15:08) Broader metabolic impact
(20:27) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.
Website: The GLP-1 Podcast Show
Instagram: The GLP-1 Podcast Show
LinkedIn: The GLP-1 Podcast Show

In this episode of The GLP-1 Podcast Show, I speak with Dr. Michael Nauck, Head of Clinical Research at the Diabetes Division of St. Josef-Hospital, Ruhr-University Bochum, Germany. We explore the early discoveries behind incretin hormones, the development of GLP-1–based therapies, and their expanding role in diabetes, obesity, and cardiovascular care. Dr. Nauck also discusses the next generation of dual and triple agonists shaping obesity medicine. Listen now on all major platforms.

“For the first time, weight loss medications, like GLP-1, achieved meaningful reductions without serious safety concerns.”

Meet the guest: Dr. Michael Nauck is Head of Clinical Research at the Diabetes Division, St. Josef-Hospital, Ruhr-University Bochum, Germany. His pioneering work on incretin hormones established the scientific foundation for GLP-1–based therapies in type 2 diabetes. With a research focus on metabolic regulation and cardiovascular outcomes, Dr. Nauck continues to advance innovation in endocrinology and obesity care.

What you will learn:
(00:00) Highlight
(01:09) Introduction
(02:18) Incretin effect explained
(06:38) Early GLP-1 discoveries
(08:39) DPP-4 inhibitors’ role
(12:12) Beyond glucose control
(16:44) Mechanisms of GLP-1
(22:51) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.
Website: The GLP-1 Podcast Show
Instagram: The GLP-1 Podcast Show
LinkedIn: The GLP-1 Podcast Show

The GLP-1 Podcast Show is a new podcast created to spotlight the science, perspectives, and leaders shaping the future of obesity treatment and metabolic medicine. In this first episode, we welcome Dr. Michael Schwartz, Robert H. Williams Endowed Chair and Professor of Medicine at the University of Washington, who speaks with Areesha Moiz about how GLP-1 receptor agonists reshape obesity treatment. The discussion covers adaptive responses to weight loss, brain regulation of appetite, mechanisms of long-acting drugs, and the challenges of sustaining results after treatment withdrawal. It also highlights emerging therapeutic strategies to prolong weight loss. Listen now on all major platforms!

"GLP-1 receptor agonists are unique because they continuously and maximally activate their target, creating effects that natural peptides could never achieve."

Meet the guest: Dr. Michael Schwartz received his MD from Rush Medical College and trained in endocrinology and metabolism at the University of Washington. He is internationally recognized for his research on brain mechanisms controlling body weight, glucose homeostasis, obesity, and diabetes. A recipient of numerous awards, Dr. Schwartz has published nearly 300 papers and directed major research institutes in Seattle.

What you will learn:
(00:00) Highlight
(01:15) Introduction
(03:26) GLP-1 drug design
(07:51) Appetite regulation
(10:23) Adaptive response
(14:39) Weight regain
(17:55) Maintenance strategies
(24:44) Final Questions

𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺.
Website: The GLP-1 Podcast Show
Instagram: The GLP-1 Podcast Show
LinkedIn: The GLP-1 Podcast Show